Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.78 |
| ▸ | FLT3 | P36888 | 13/20 | 0.78 |
| ▸ | BLK | P51451 | 11/20 | 0.78 |
| ▸ | CDK4 | P11802 | 1/20 | 0.67 |
| ▸ | CCND1 | P24385 | 1/20 | 0.67 |
| ▸ | CCND2 | P30279 | 1/20 | 0.67 |
| ▸ | CCND3 | P30281 | 1/20 | 0.67 |
| ▸ | BTK | Q06187 | 6/20 | 0.67 |
| ▸ | ITK | Q08881 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15752456 | 0.93 | EGFR (0.67) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752413 | 0.93 | EGFR (0.67) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752327 | 0.92 | EGFR (0.66) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752372 | 0.91 | EGFR (0.65) | EGFRFLT3BLKBTKITK | |
| SCHEMBL15752541 | 0.91 | EGFR (0.65) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752331 | 0.90 | EGFR (0.64) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752571 | 0.90 | EGFR (0.63) | EGFRFLT3BLKBTKITK | |
| SCHEMBL15752481 | 0.90 | EGFR (0.64) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752488 | 0.90 | EGFR (0.66) | EGFRFLT3BLKCDK4CCND1 | |
| SCHEMBL15752598 | 0.90 | EGFR (0.66) | EGFRFLT3BLKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014079232-A1 | 7-OXO-PYRIDOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国科学院广州生物医药与健康研究院 (CN) | 2014-05-30 | — | — | WO | disclosed |